Expert Testimony on DEA Marijuana Rescheduling Proposal Delayed to January or February 2025
November 5, 2024 | Cannabis Law Updates
Although last week the U.S. Drug Enforcement Agency’s Administrator, Anne Milgram, approved over two dozen witnesses to testify at the upcoming December 2, 2024, hearing on the Biden administration’s rescheduling proposal, a few days later Chief Administrative Law Judge John Mulrooney took issue with the qualifications of those witnesses and issued a preliminary order postponing testimony to January or February 2025. Judge Mulrooney’s comments on the list evidenced some frustration that DEA had not included basic contact information and the witnesses’ position on rescheduling. He directed the DEA to supplement the witness list by November 12.
DEA-selected witnesses include the National Cannabis Industry Association (NCIA), various state agencies, educators, and science organizations.
The administrative process for rescheduling marijuana from Schedule I (like heroin and fentanyl) to Schedule III (like anabolic steroids and Tylenol with codeine) may be lengthy and complicated, and the outcome uncertain. We will continue monitoring DEA decisions on this front. We will provide additional details and updates as they become available.
Disclaimer: This content may be an attorney advertisement. The information provided on this website does not constitute legal advice. All information, content, and materials available on this website are for general informational purposes only, and might not be up to date. The content on this website is provided “as is,” and no representations are made that the content is free of error. Usage of this website or any resources contained within it does not create an attorney-client relationship between user and Zuber Lawler (or any of its attorneys). Readers of this website should contact their attorney to obtain advice with respect to any particular legal matter. Any and all liability with respect to actions taken or not taken based on the contents of this website are hereby expressly disclaimed.
Recent Updates
An FDA Panel Just Voted to Widen Access to Peptides. Here’s What It Actually Means for the Longevity Space July 30, 2026
Generative AI Legal Issues: 5 Critical Questions Every Business Must Answer Before Deploying AI Solutions May 21, 2026
Medical Rescheduling, Recreational Risk: How Schedule III Could Reshape Adult-Use Cannabis February 18, 2026
Schedule III Cannabis: FDA’s New Frontier January 27, 2026
Data Privacy and AI in Longevity: Legal Risks Around Predictive Biomarkers and Health Data January 23, 2026
2026 Employment Law Developments: Key Takeaways for Employers December 22, 2025